Sector Update: Healthcare Shares Slightly Higher in Pre-Market; Vanda Pharmaceuticals Down 11% on Sustained Decline


Shutterstock photo

Health care stocks:

JNJ: +0.08%

PFE: -0.20%

ABT: flat

MRK: +0.13%

AMGN: +0.10%

Healthcare shares are a bit higher pre-market. Eli Lilly's ( LLY ) drug Zyprexa is being investigated by the FDA after two patients died after taking it, Bloomberg reports. Zyprexa is an antipsychotic. Eli Lilly shares are flat in pre-market at $52.35.

Also, Bristol-Myers Squibb Company ( BMY ) and AstraZeneca ( AZN ) say results of the Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza met the primary safety objective of non-inferiority.

But it did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care versus a placebo. BMY is flat at $46.85 in pre-market trade; AZN is down 0.3% at $50.81.

Finally, Vanda Pharmaceuticals ( VNDA ) shares, which have been struggling all week in the wake of data on Tasimelteon studies, have sunk more than 11% pre-market.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities
More Headlines for: AZN , BMY , LLY , VNDA

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by